All NotesCorporate LawIntellectual Property Rights (IPR)

IPR

Topic 153 Pharmaceutical IP

Topic 153 — Pharmaceutical IP Deep-Dive

This Module 17 opens INDUSTRY DEEP-DIVES — examining IP frameworks across major Indian industries through specialised lenses. The judiciary aspirant who has mastered M1-M16 now applies that knowledge to specific sectoral contexts where IP plays foundational roles. PHARMACEUTICAL IP is uniquely critical in India — the country is the world's largest supplier of generic medicines (40% of US generic supply; 25% of UK generic supply) and has a $50+ billion pharmaceutical industry. India became known as the "PHARMACY OF THE WORLD" through a historically generic-friendly framework that began transforming in 2005 when India implemented TRIPS-mandated PRODUCT PATENT PROTECTION for pharmaceuticals (previously only process patents allowed). The 2005 transition required CAREFUL BALANCING of: (1) TRIPS COMPLIANCE; (2) ACCESS TO MEDICINES; (3) LOCAL INDUSTRY DEVELOPMENT; (4) INNOVATION INCENTIVES. The Indian framework solves this through several distinctive provisions: SECTION 3(d) — anti-evergreening (NOVARTIS v. UoI 2013 4 SCC 119 GLEEVEC case affirming strict efficacy test); SECTION 84 — robust compulsory licensing (NATCO v. BAYER 2012 Sorafenib first compulsory licence; NATCO v. BAYER LPA No 359/2017 Bolar exception); SECTION 107A — BOLAR EXCEPTION broader than US equivalent (BAYER CORPORATION v. UoI 2019 broadened to include exports for regulatory research); SECTION 92 — government use during emergencies; SECTION 100 — government acquisition; SECTION 47 — research/private use exception; SECTION 25(1)+(2) — robust pre-grant + post-grant opposition (NOVARTIS, GLAXO, BMS oppositions). India does NOT have data exclusivity or patent linkage (unlike US Hatch-Waxman framework). The DRUGS PRICES CONTROL ORDERS under Essential Commodities Act 1955 + DRUG PRICE CONTROL ORDER (DPCO) 2013 control essential medicine pricing. Recent landmark cases: NOVARTIS 2013 SCC 119 GLEEVEC; BAYER v. NATCO 2014 BomHC compulsory licence; BAYER v. UoI 2019 Bolar; AVENTIS v. ALGREAT 2025 ₹5L+4 weeks imprisonment; NATCO v. BAYER 2012 first Section 84 grant. INTERNATIONAL framework: TRIPS Article 27 + 31; Doha Declaration 2001 (India lead); MC12 Decision 2022 vaccines/diagnostics/therapeutics waiver; Marrakesh Treaty 2014 (India member). This topic walks through every aspect of pharmaceutical IP — Section 3(d) jurisprudence, Section 84 compulsory licensing, Section 107A Bolar exception, drug pricing, and recent reforms.

1. Module 17 — Industry Deep-Dives Overview

153

PHARMA

Section 3(d) + 84 + Bolar

154

TECH

CRI + SEP/FRAND + AI

155

BIOTECH

Section 3(j) + Biodiversity

156

FMCG

TM + Designs + Trade Dress

157

BANK/FINTECH

Software + UI + branding

158

HEALTH

medical devices + diagnostics

159

EDUCATION

EdTech + content + platforms

160

M17 MASTER

industry compendium

2. Indian Pharmaceutical Industry — Foundational Framework

A. Industry Scale + Strategic Importance

✅ India's Pharmaceutical Industry

GLOBAL POSITIONING: · World's LARGEST supplier of generic medicines. · 40% of US generic supply. · 25% of UK generic supply. · $50+ billion industry. · "PHARMACY OF THE WORLD". · Top 10 global pharma destinations. MAJOR PLAYERS: · Sun Pharmaceutical (largest Indian). · Cipla. · Lupin. · Dr. Reddy's Laboratories. · Aurobindo Pharma. · Cadila Healthcare. · Glenmark. · Torrent Pharmaceuticals. · Biocon (biotech). · Natco (compulsory licensing leader). KEY SEGMENTS: · Generics (60%+ of industry). · Active Pharmaceutical Ingredients (API). · Biosimilars. · Vaccines (Serum Institute world's largest). · Specialty + complex generics. STRATEGIC IMPORTANCE: · Public health. · Foreign exchange earner. · Employment generator. · South-South cooperation. · Emerging market leader.

B. The 2005 TRIPS Transition

  • Pre-2005: Process patents only (Patents Act 1970 framework).
  • 1995-2005: Mailbox provision; pipeline.
  • 1 January 2005: Product patents introduced.
  • Patent (Amendment) Act 2005 — comprehensive reform.
  • Section 3(d) introduced — anti-evergreening.
  • TRIPS Article 27 compliance.
  • Section 84 robust compulsory licensing preserved.
  • Section 107A Bolar exception introduced.

3. Section 3(d) — Anti-Evergreening Workshop

A. The Statutory Provision

Section 3(d) Patents Act 1970

"3. What are not inventions.—The following are not inventions within the meaning of this Act,— (d) the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance or the mere discovery of any new property or new use for a known substance or of the mere use of a known process, machine or apparatus unless such known process results in a new product or employs at least one new reactant. Explanation.—For the purposes of this clause, salts, esters, ethers, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, combinations and other derivatives of known substance shall be considered to be the same substance, unless they differ significantly in properties with regard to efficacy."

B. Novartis v. UoI 2013 — The Foundational Case

📖 Novartis AG v. Union of India, (2013) 6 SCC 1; AIR 2013 SC 1311

Background — Novartis filed for patent on imatinib mesylate beta-crystalline form (GLEEVEC) for chronic myeloid leukaemia.

Issue — Whether new crystalline form of known molecule passes Section 3(d) "enhanced efficacy" test.

Holding — Supreme Court: REJECTED Novartis application. "Enhanced efficacy" means THERAPEUTIC EFFICACY, not just any property enhancement. Improved bioavailability ALONE is INSUFFICIENT.

Significance — DEFINITIVE Section 3(d) interpretation; cornerstone of Indian pharma IP framework; rejected pharmaceutical evergreening attempts.

Workshop Lesson — For new forms, demonstrate THERAPEUTIC efficacy enhancement; mere property changes insufficient.

C. Section 3(d) Application Framework

✅ Section 3(d) Application Workshop

WHAT IS COVERED (treated as same substance): · Salts. · Esters. · Ethers. · Polymorphs. · Metabolites. · Pure forms. · Particle size variations. · Isomers. · Mixtures of isomers. · Complexes. · Combinations. · Other derivatives. ESCAPE CLAUSE — must demonstrate: · SIGNIFICANT difference in properties with regard to efficacy. · THERAPEUTIC efficacy enhancement (Novartis 2013). · Not mere bioavailability improvement. · Not mere stability improvement. · Not mere solubility improvement. · Not mere dissolution improvement. DRAFTING IMPLICATIONS: · Provide clinical efficacy data. · Compare to reference compound. · Document therapeutic enhancement. · Address Section 3(d) head-on in specification. RECENT TRENDS: · Increased Section 3(d) use against secondary patents. · Increasing use against PRIMARY patents (concerning). · Sampat & Shadlen 2018 study. · Continued rigorous application.

4. Section 84 — Compulsory Licensing Framework

A. The Statutory Provision

Section 84(1) Patents Act 1970

"84. Compulsory licences.—(1) At any time after the expiration of three years from the date of the grant of a patent, any person interested may make an application to the Controller for grant of compulsory licence on patent on any of the following grounds, namely:— (a) that the reasonable requirements of the public with respect to the patented invention have not been satisfied; or (b) that the patented invention is not available to the public at a reasonably affordable price; or (c) that the patented invention is not worked in the territory of India."

B. Natco v. Bayer 2012 — First Compulsory Licence

📖 Natco Pharma Ltd. v. Bayer Corporation, MANU/IC/0050/2012 (Patent Office); upheld in BomHC

Background — Bayer's SORAFENIB (Nexavar) for kidney/liver cancer; ₹2.8L per month.

Issue — Whether Section 84 compulsory licence justified.

Holding — Patent Office (12 March 2012): Granted FIRST EVER Indian compulsory licence to Natco. Bayer's pricing (~₹2.8L/month) unaffordable; reasonable requirements unmet; not adequately worked in India.

Royalty — 6% royalty paid to Bayer.

Significance — DEFINITIVE Section 84 framework demonstration; pharmaceutical pricing pressure; access to medicines doctrine.

Workshop Lesson — For compulsory licensing, demonstrate (a) unmet public requirements; (b) unaffordability; OR (c) inadequate working.

C. Section 84 Application Workshop

✅ Section 84 Compulsory Licensing Workshop

TIMING: · After 3 years from grant. · Person interested standing. GROUNDS (any one sufficient): 1. Reasonable public requirements not satisfied. 2. Not reasonably affordable price. 3. Not worked in India. FACTORS CONSIDERED: · Manufacturing in India. · Adequate import. · Local production capacity. · Pricing reasonableness. · Public health needs. · Industrial activity. GROUNDS FOR REASONABLE PUBLIC REQUIREMENTS: · Section 84(7) framework. · Adequate manufacturing. · Adequate import. · Affordable pricing. · Reasonable terms. LICENCE TERMS: · Royalty determined by Controller. · Quality standards. · Specific working obligations. · Reporting requirements. · Term limited. APPEALS: · Section 117A — to HC IP Division. · 3 months timeline. INTERNATIONAL FRAMEWORK: · TRIPS Article 31 framework. · Doha Declaration 2001 (India lead). · MC12 Decision 2022 (vaccines/diagnostics/therapeutics).

5. Section 107A — Bolar Exception

A. The Statutory Provision

Section 107A Patents Act 1970

"107A. Certain acts not to be considered as infringement.—For the purposes of this Act,— (a) any act of making, constructing, using, selling or importing a patented invention solely for uses reasonably related to the development and submission of information required under any law for the time being in force, in India, or in a country other than India, that regulates the manufacture, construction, use, sale or import of any product..."

B. Bayer v. UoI 2019 — Broad Bolar Interpretation

📖 Bayer Corporation v. Union of India, LPA No. 359/2017 (Del HC division bench, 2019)

Background — Bayer challenged Natco's export of Sorafenib for clinical trials in China.

Issue — Whether Section 107A permits export for foreign regulatory research.

Holding — Delhi HC: Section 107A PERMITS EXPORT for foreign regulatory research. "Sale" includes export. Broader than US Hatch-Waxman equivalent.

Significance — Broad and flexible Bolar interpretation; favours generic industry; enables research collaboration.

Workshop Lesson — For Bolar protection, can include exports for regulatory research; broader Indian framework.

C. Bolar Exception Application Workshop

✅ Section 107A Application Workshop

COVERED ACTIVITIES: · Making. · Constructing. · Using. · Selling (including export per Bayer 2019). · Importing. PURPOSE REQUIREMENT: · "Solely" for uses related to regulatory development. · Regulatory submission preparation. · Pre-launch generic preparation. · Clinical trials. · Bioequivalence studies. · Regulatory approvals. GEOGRAPHIC SCOPE: · India regulatory. · Foreign regulatory (per Bayer 2019). · International collaboration enabled. ADVANTAGES OVER US HATCH-WAXMAN: · No territorial limitation. · Broader scope of activities. · "Sale" includes export. STRATEGIC IMPLICATIONS: · Generic industry foundation. · Pre-launch advantages. · Clinical trial support. · Research collaboration. · Regulatory approval pathway.

6. Pre-Grant + Post-Grant Opposition for Pharma

A. Pharmaceutical Opposition Strategy

  • Section 25(1) — Pre-grant opposition by ANY PERSON.
  • Section 25(2) — Post-grant by PERSON INTERESTED only.
  • Pharma oppositions historically aggressive.
  • Section 3(d) frequent ground.
  • Section 3(j) for biotech.
  • Novelty + inventive step.
  • Section 8 compliance.

B. Notable Pharma Opposition Cases

  • Novartis (Glivec) — pre-grant opposition by India Cancer Patients Aid Association.
  • GlaxoSmithKline pediatric formulation oppositions.
  • BMS HIV/AIDS drug oppositions.
  • Roche oncology drug oppositions.
  • Pfizer Sutent (oncology) opposition framework.
  • Multiple successful Section 3(d) oppositions.

7. Drug Pricing Framework

A. Drug Price Control Order (DPCO) 2013

✅ DPCO 2013 Framework

STATUTORY BASIS: · Essential Commodities Act 1955 — Section 3. · Drugs Prices Control Orders. · DPCO 2013 (replacing 1995, 2005). SCOPE: · Essential medicines listed in National List of Essential Medicines (NLEM). · ~870 medicines covered. · Specific formulations. PRICING MECHANISM: · Market-based pricing. · Simple average of prices of brands above 1% market share. · 16% margin allowed for trade. · No re-fixing for brands lower than 1%. ADJUSTMENT MECHANISM: · Annual WPI-based adjustments. · Periodic review. · Price violation penalties. OBJECTIVES: · Affordable access to essential medicines. · Public health priority. · Industry sustainability. · Balance with Section 84 framework. INTERSECTION WITH IP: · Patents + price controls coexist. · Compulsory licensing complementary. · Section 92 government use linkage.

B. Differential Pricing

  • Public hospital tier pricing.
  • Private hospital tier pricing.
  • Retail consumer pricing.
  • Government procurement pricing.
  • Donation/access programmes.

8. Recent Pharmaceutical IP Cases

📖 Aventis Pharma S.A. v. Algreat Industries, 3 February 2025 (Del HC)

Background — Pharmaceutical patent enforcement.

Holding — ₹5 lakh damages + 4 WEEKS IMPRISONMENT for contempt.

Significance — Strong patent enforcement; criminal sanctions; deterrent.

📖 Bayer Intellectual Property GMBH v. Alembic Pharmaceuticals, RFA(OS)(Comm) 6/2017 (Del HC 2019)

Background — Rivaroxaban patent and Bolar exception.

Holding — Section 107A includes exports for foreign regulatory research.

Significance — Companion case to Bayer v. Natco 2019.

📖 Novartis AG v. Union of India, (2013) 6 SCC 1

Background — Glivec/Imatinib mesylate beta-crystalline form.

Holding — Supreme Court: Strict Section 3(d) test.

Significance — Cornerstone Indian pharma IP jurisprudence.

9. Strategic Considerations

✅ For pharma companies — eight points

For new drug applications, navigate Section 3(d) with therapeutic efficacy data.

For secondary patents, anticipate increased Section 3(d) scrutiny.

For pricing, integrate DPCO 2013 framework.

For compulsory licensing risk, monitor Section 84 grounds.

For Bolar protection, leverage Section 107A broad interpretation.

For oppositions, prepare comprehensive evidence base.

For international, leverage Doha Declaration framework.

For enforcement, leverage Aventis 2025 framework.

10. Memory Aid — Quick Recall

✅ Quick Recall — Pharmaceutical IP

India largest generic supplier; "Pharmacy of the World".

2005 TRIPS transition — product patents introduced.

Section 3(d) — anti-evergreening (Novartis 2013).

Therapeutic efficacy enhancement required (not bioavailability alone).

Section 84 — compulsory licensing (Natco v. Bayer 2012 first grant).

6% royalty in Natco-Bayer.

Section 107A — Bolar exception (Bayer v. UoI 2019 broad).

Includes export for foreign regulatory research.

Section 92 — government use; Section 100 — government acquisition.

Section 25(1)+(2) — pre/post-grant opposition.

DPCO 2013 — Drug Price Control Order under Essential Commodities Act 1955.

NLEM — National List of Essential Medicines (~870 medicines).

Doha Declaration 2001 — India lead role.

MC12 Decision 2022 — vaccines/diagnostics/therapeutics.

🎯 EXAM POINTERS — TOPIC 153

  • India largest generic medicine supplier; 40% US, 25% UK supply; "Pharmacy of the World".
  • Patent (Amendment) Act 2005 — TRIPS-mandated product patents.
  • Section 3(d) Patents Act — anti-evergreening (introduced 2005).
  • Section 3(d) Explanation — salts, esters, ethers, polymorphs, metabolites, pure form, particle size, isomers, mixtures, complexes, combinations same substance unless significantly different in efficacy.
  • Novartis AG v. Union of India (2013 6 SCC 1; AIR 2013 SC 1311) — DEFINITIVE Section 3(d) interpretation.
  • "Enhanced efficacy" = THERAPEUTIC efficacy (not bioavailability/solubility/stability/dissolution alone).
  • Section 84 Patents Act — compulsory licensing; after 3 years from grant; person interested.
  • Section 84 grounds: (a) reasonable public requirements not satisfied; (b) not affordable; (c) not worked in India.
  • Natco Pharma v. Bayer Corporation (MANU/IC/0050/2012; Patent Office 12 March 2012) — FIRST EVER Indian compulsory licence; Sorafenib/Nexavar; 6% royalty.
  • Section 107A Patents Act — Bolar exception (introduced 2002).
  • Bayer Corporation v. UoI (LPA 359/2017; Del HC 2019) — Section 107A includes export for foreign regulatory research.
  • Bayer v. Alembic Pharmaceuticals (RFA(OS)(Comm) 6/2017; Del HC 2019) — Rivaroxaban + Bolar.
  • Section 92 — government use during emergency.
  • Section 100 — government acquisition.
  • Section 47 — research/private use exception.
  • Section 25(1) — pre-grant opposition (any person); Section 25(2) — post-grant (person interested; 12 months).
  • India does NOT have data exclusivity (unlike US Hatch-Waxman 5 years).
  • India does NOT have patent linkage.
  • DPCO 2013 — Drug Price Control Order; ~870 essential medicines.
  • Essential Commodities Act 1955 Section 3 — DPCO statutory basis.
  • NLEM — National List of Essential Medicines.
  • Doha Declaration 2001 — India lead role.
  • MC12 Decision (June 2022) — vaccines/diagnostics/therapeutics waiver.
  • Aventis v. Algreat (3 February 2025) — ₹5L + 4 weeks imprisonment.
  • TRIPS Article 27 + 31 — patent + compulsory licensing framework.